Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBITDA (2022 - 2026)

Indivior Pharmaceuticals has reported EBITDA over the past 5 years, most recently at $137.0 million for Q1 2026.

  • For Q1 2026, EBITDA rose 179.59% year-over-year to $137.0 million; the TTM value through Mar 2026 reached $281.0 million, up 751.52%, while the annual FY2025 figure was $262.0 million, 1239.13% up from the prior year.
  • EBITDA for Q1 2026 was $137.0 million at Indivior Pharmaceuticals, up from $81.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $137.0 million in Q1 2026 and troughed at -$258.0 million in Q4 2022.
  • A 5-year average of $14.3 million and a median of $52.5 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 426.79% in 2023 and later soared 179.59% in 2026.
  • Year by year, EBITDA stood at -$258.0 million in 2022, then soared by 123.26% to $60.0 million in 2023, then fell by 23.33% to $46.0 million in 2024, then skyrocketed by 76.09% to $81.0 million in 2025, then skyrocketed by 69.14% to $137.0 million in 2026.
  • Business Quant data shows EBITDA for INDV at $137.0 million in Q1 2026, $81.0 million in Q4 2025, and $43.0 million in Q3 2025.